IDWeek 2018

Omadacycline is a new intravenous/oral antibiotic for patients presenting in the emergency department with acute bacterial skin and soft tissue infections. Read More ›

In 2 parallel phase 3 trials, the diaminopyrimidine reductase inhibitor iclaprim showed noninferiority compared with vancomycin for the treatment of wound infections. Read More ›

Identifying social vulnerabilities that likely impact pediatric outpatient antimicrobial treatment after discharge could better enable treatment customization or prompt care coordination. Read More ›

Although community-acquired pneumonia (CAP) guidelines recommend transition to an oral beta-lactam regimen or fluoroquinolone (FQ) when patients are clinically stable, the collateral damage associated with FQ usage has led stewardship efforts to reduce initial FQ usage in CAP therapy. Read More ›

The US Food and Drug Administration has approved omadacycline for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Read More ›

A dedicated infectious disease stewardship program can have immediate impact on patient safety, treatment of appropriate disease states, and the reduction of unnecessary readmission to the acute care hospital. Read More ›

Shortening the duration of antimicrobial therapy to that recommended in guidelines may reduce the risk for collateral damage due to Clostridium difficile infection. Read More ›

The researchers assessed the impact of antimicrobial stewardship program interventions in elderly patients on 30-day readmissions due to treatment failure and decreased antibiotic expenditures per adjusted patient-day. Read More ›

A pooled analysis showed favorable safety results from phase 3 studies of omadacycline, a new once-daily intravenous/oral therapy for the monotherapy of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Read More ›

Pooled safety data of eravacycline in 3 comparator-controlled studies for the treatment of complicated intra-abdominal infections showed that it was generally well-tolerated compared with ertapenem and meropenem. Read More ›

Page 2 of 3